Sympathetic blockade prevents the decrease in cardiac VEGF expression and capillary supply in experimental renal

K Amann1, G Odoni, K Benz

  • 1Department of Pathology, University of Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany. kerstin.amann@uk-erlangen.de

Insights

Kidney failure reduces cardiac vascular endothelial growth factor (VEGF) in rats, impairing heart function. Blocking the sympathetic nervous system may improve cardiac VEGF levels and heart health.

Area of Science:

  • Cardiovascular research
  • Renal disease mechanisms
  • Molecular biology

Background:

  • Uremic cardiomyopathy is linked to reduced myocardial capillary supply.
  • Sympathetic nervous system blockade can prevent cardiac issues in uremic rats.
  • The role of vascular endothelial growth factor (VEGF) in uremic cardiomyopathy is unclear.

Purpose of the Study:

  • To investigate if cardiac vascular endothelial growth factor (VEGF) gene and protein expression are altered in experimental renal failure.
  • To determine the effect of sympathetic nervous system downregulation on cardiac VEGF expression and myocardial capillary supply in rats with renal failure.

Main Methods:

  • Long-term study: Compared VEGF gene and protein expression and capillary supply in Sprague-Dawley rats with subtotal nephrectomy (SNX) versus sham operation.
  • Short-term study: Analyzed the effect of renal denervation on cardiac VEGF, flt-1, and flk-1 gene expression and myocardial capillary supply in SNX rats.

Main Results:

  • Long-term: SNX rats showed significantly lower cardiac capillary supply and VEGF gene/protein expression compared to sham rats.
  • Short-term: Untreated SNX rats had significantly lower cardiac VEGF mRNA expression than sham rats.
  • Renal denervation prevented the decrease in cardiac VEGF mRNA expression in SNX rats.

Conclusions:

  • Cardiac VEGF gene and protein expression are reduced in experimental renal failure.
  • Reduced cardiac VEGF may contribute to impaired myocardial adaptation and hypertrophy in renal failure.
  • Sympathetic nervous system downregulation may improve cardiac structure and function in renal failure partly via increased cardiac VEGF expression.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...